Proposition - PharmXpert Academy
Proposition - PharmXpert Academy
Proposition - PharmXpert Academy
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
540 2007 Korea Pharmaceutical Industry Directory<br />
3. R&D Figures<br />
No<br />
Classification<br />
Section<br />
(Bio,<br />
Synthesis)<br />
The Name of<br />
Technology<br />
Main<br />
Ingredient<br />
Use<br />
(Indications)<br />
The Duration<br />
of<br />
Development<br />
The Stage<br />
of<br />
Development<br />
Future<br />
Plan<br />
Expected<br />
Licencing<br />
(Domestic,<br />
Oversea)<br />
1 New drug Natural<br />
product<br />
Dementia<br />
treatment<br />
development<br />
from natural<br />
herbal extract<br />
INM-176 Dementua Phase 2<br />
2<br />
Advanced<br />
process<br />
Natural<br />
product<br />
Immunoactive<br />
anti-cancer<br />
drug<br />
development<br />
using Phellinus<br />
linteus mycelia<br />
culture system<br />
Phellinus<br />
linteus<br />
mycelium<br />
extract<br />
Anti-cancer 4 years Approved<br />
4. Patent Information<br />
No<br />
1<br />
2<br />
3<br />
4<br />
5<br />
6<br />
7<br />
8<br />
9<br />
The Name of Technology<br />
Alprostadil-containing<br />
composition for external use<br />
Amitriptyline granule as a<br />
controlled release system<br />
and the preparation method<br />
thereof<br />
A process for producing<br />
polysaccharide from<br />
Phellinus linteus mycelium<br />
Bioreactor for the culture of<br />
microorganisms<br />
Process for mass production<br />
of Phellius linteus<br />
byfed-batch culture<br />
Alprostadil-containing<br />
composition for external<br />
application<br />
A novel Phellinus linteus<br />
strain and an anticancer<br />
immunoactive<br />
polysaccharide prepared<br />
therefrom<br />
Composition of itraconazole<br />
for oral administration and<br />
process for preparing<br />
thereof<br />
Alprostadil<br />
alkylester-containing<br />
comporition fro external<br />
application<br />
Application<br />
No.<br />
(Application<br />
date)<br />
1999-0031090<br />
(1999.07.29)<br />
1999-0039518<br />
(1999.09.15)<br />
2000-0018173<br />
(2000.04.07)<br />
2000-0018176<br />
(2000.040.07)<br />
2000-0033132<br />
(2000.06.16)<br />
2000-0034767<br />
(2000.06.23)<br />
2001-003264<br />
(2001.01.19)<br />
2001-075306<br />
(2001.11.30)<br />
2001-0080418<br />
(2001.12.18)<br />
Publication<br />
No.<br />
(Publication<br />
date)<br />
0453803<br />
(2004.10.12)<br />
0341664<br />
(2002.06.11)<br />
0368681<br />
(2003.01.07)<br />
0369240<br />
(2003.01.09)<br />
0383078<br />
(2003.04.23)<br />
0402334<br />
(2003.10.07)<br />
0428518<br />
(2004.04.12)<br />
0441745<br />
(2004.07.15)<br />
Priority<br />
No.<br />
Applied<br />
Country For<br />
Global<br />
USA<br />
(US6,500,440)<br />
USA<br />
(US6,673,841)<br />
Development<br />
Stage<br />
Future<br />
Plan<br />
Expected<br />
Licencing<br />
(Domestic,<br />
Oversea)
Change language